Key Takeaways ACAD posted Q4 EPS of 16 cents, topping estimates, as revenues rose 9% to $284M.Nuplazid sales rose 7% to $174.4M, while Daybue climbed 13% to $109.6M.ACAD guides 2026 revenues of $1.22-$1.28B; EU review of trofinetide faces likely CHMP rejection.Acadia Pharmaceuticals (ACAD) reported fourth-quarter 2025 earnings per share (EPS) of 16 cents (excluding tax benefit), which beat the Zacks Consensus Estimate of 12 cents. In the year-ago quarter, the company had reported adjusted EPS of 17 cents.In ...

Core Viewpoint - Acadia Pharmaceuticals reported quarterly earnings of $0.16 per share, exceeding the Zacks Consensus Estimate of $0.12 per share, but down from $0.17 per share a year ago, indicating a mixed performance in earnings despite a positive surprise [1][2]. Financial Performance - The company achieved revenues of $283.99 million for the quarter ended December 2025, which fell short of the Zacks Consensus Estimate by 2.94%, compared to $259.6 million in the same quarter last year [2]. - Over the last four quarters, Acadia has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2]. Stock Performance - Acadia shares have declined approximately 7.9% since the beginning of the year, contrasting with the S&P 500's gain of 0.7% [3]. - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6]. Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.16 on revenues of $268.17 million, and for the current fiscal year, it is $0.68 on revenues of $1.19 billion [7]. - The trend of earnings estimate revisions for Acadia was mixed prior to the earnings release, which may influence future stock movements [6]. Industry Context - The Medical - Biomedical and Genetics industry, to which Acadia belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 06-1376651 (State or Other Jurisdi ...

ACADIA Pharmaceuticals (NasdaqGS:ACAD) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsAl Kildani - Senior Vice President of Investor Relations and Corporate CommunicationsAsh Verma - DirectorCaroline Palavicino-Maggio - VPCatherine Owen Adams - CEODavid Hoang - DirectorElizabeth Thompson - EVP and Head of Research and DevelopmentJason Butler - Managing DirectorJulian Pino - AssociateMarc Goodman - Senior Managing Director in NeuroscienceMark Breidenbach - DirectorMark Schneyer - CFO ...

ACADIA Pharmaceuticals (NasdaqGS:ACAD) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsAl Kildani - Senior Vice President of Investor Relations and Corporate CommunicationsAsh Verma - DirectorCaroline Palavicino-Maggio - VPCatherine Owen Adams - CEODavid Hoang - DirectorElizabeth Thompson - EVP and Head of Research and DevelopmentJason Butler - Managing DirectorJulian Pino - AssociateMarc Goodman - Senior Managing Director in NeuroscienceMark Breidenbach - DirectorMark Schneyer - CFO ...

ACADIA Pharmaceuticals (NasdaqGS:ACAD) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker11Thank you for standing by. My name is J.L., and I will be your conference operator today. At this time, I would like to welcome everyone to the ACADIA Pharmaceuticals Inc. fourth quarter earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press s ...

Fourth Quarter and Full Year 2025 Earnings Call February 25, 2026 Call Agenda Catherine Owen Adams Chief Executive Officer Welcome Commercial Update Tom Garner Executive Vice President, Chief Commercial Officer Elizabeth H.Z. Thompson, Ph.D. Executive Vice President, Head of Research and Development R&D Update Financial Update Mark Schneyer Executive Vice President, Chief Financial Officer Al Kildani Senior Vice President, IR and Corporate Communications CEO Opening Remarks Closing Remarks Catherine Owen Ad ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.Considering buying HSIC stock? Here’s what analysts think: Photo via Shutterstock ...

Core Viewpoint - Acadia Pharmaceuticals (ACAD) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending December 2025, with the consensus outlook indicating a significant impact on its stock price based on actual results compared to estimates [1][2]. Earnings Expectations - The upcoming earnings report is expected to show earnings of $0.12 per share, reflecting a year-over-year decrease of 29.4%, while revenues are projected to be $292.58 million, representing a 12.7% increase from the previous year [3]. - The consensus EPS estimate has been revised 3.23% higher in the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4]. Earnings Surprise Prediction - The Zacks Earnings ESP (Expected Surprise Prediction) model suggests that a positive Earnings ESP reading of +14.92% indicates a likelihood of Acadia beating the consensus EPS estimate, although the company currently holds a Zacks Rank of 3 [12]. - Historical performance shows that Acadia has beaten consensus EPS estimates three out of the last four quarters, with a notable surprise of +85.71% in the last reported quarter [13][14]. Industry Context - Day One Biopharmaceuticals, another player in the same industry, is expected to report a loss of $0.17 per share for the same quarter, which is a year-over-year increase of 75.4%, with revenues expected to rise by 65.1% to $48.22 million [18][19]. - Despite a significant upward revision of 53.1% in the consensus EPS estimate for Day One Biopharmaceuticals over the last 30 days, it currently has a negative Earnings ESP of -29.00%, complicating predictions for beating the consensus EPS estimate [19][20].

Core Insights - Maverick Capital Ltd. established long positions in Google C, Applied Materials, Boston Scientific, Visa, and Camden Property during the fourth quarter [1] - The firm increased its holdings in TSMC, NVIDIA, GFL Environment, and Carvana [1] - Maverick Capital completely exited positions in Kenvue, US Bancorp, AMD, Danaher, and Insmed [1] - The company reduced its stakes in Nubank, Disney, Merit Medical, Acadia Health, and Sherwin-Williams [1] - The firm maintains significant positions in NVIDIA, Microsoft, Amazon, TSMC, and Google C [1]